Drug Profile
CyTIX 01
Latest Information Update: 26 Feb 2019
Price :
$50
*
At a glance
- Originator Cell-Therapy Technology Institute
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 26 Feb 2019 Discontinued - Phase-I/II for Glioma in Japan (Intradermal)
- 04 Feb 2016 CyTIX 01 is available for licensing as of 04 Feb 2016. http://www.cytix.net/
- 01 Nov 2004 Phae-I/II clinical trials in Glioma in Japan (Intradermal)